针对乳腺癌治疗的WEE1激酶:一个更新
Zhao Zhang1, Ritika Harish1, Naveed Elahi2
1Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, 100 East Lancaster Avenue, LIMR R234, Wynnewood, PA 19096, USA.
International journal of molecular sciences
|June 26, 2025
概括
WEE1激酶抑制剂对治疗乳腺癌,特别是三阴性类型的乳腺癌有前途. 新药正在开发中,具有组合疗法和改善患者反应预测的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞循环规则 细胞循环规则
背景情况:
- WEE1激酶是G2-M检查点的关键调节者,通过抑制CDK1/CDK2.2来控制进入线粒分裂的过程.
- WEE激酶家族包括WEE1,PKMYT1和WEE2,其中WEE1和PKMYT1参与了线粒体的进入,WEE2参与了半分裂.
- 在各种癌症中,WEE1是有前途的治疗标,包括耐治疗的三阴性乳腺癌.
研究的目的:
- 审查WEE1抑制治疗在乳腺癌治疗中的作用.
- 讨论新型WEE1激酶抑制剂的开发和临床评估.
- 探索潜在的组合疗法和对响应预测因子的需求.
主要方法:
- 关于WEE1激酶功能,抑制和乳腺癌治疗应用的文献综述.
- 对WEE1抑制剂的临床前和临床数据的分析.
- 检查作用机制,包括免疫调节.
主要成果:
- 目前正在探索WEE1抑制作为乳腺癌的治疗策略,临床试验中使用了几种抑制剂.
- 阿达沃谢蒂布在临床上表现有前途,但在响应变异性和副作用方面面临挑战.
- 临床前研究表明WEE1抑制剂可以通过MHC I类和STING诱导增强抗癌免疫力.
结论:
- WEE1激酶抑制剂代表了乳腺癌治疗的发展途径.
- 需要进一步的研究来确定可靠的预测对WEE1抑制的临床反应.
- 涉及WEE1抑制剂的组合疗法可能提供更高的疗效和新的治疗机会.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Canonical Wnt Signaling Pathway
9.0K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
9.0K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K


